Mead Johnson Nutrition Company (MJN)


NYSE - NYSE Real Time Price. Currency in USD
78.00+1.22 (+1.59%)
As of 3:07 PM EDT. Market open.
People also watch:
MKCIVZHRLIFFTAP
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Open77.14
Prev Close76.78
Bid78.04 x 300
Ask78.05 x 500
Day's Range76.67 - 78.33
52wk Range65.53 - 94.40
1y Target EstN/A
Market Cap14.4B
P/E Ratio (ttm)29.35
Beta1.65
Volume1,104,519
Avg Vol (3m)1,385,379
Dividend & Yield1.65 (2.15%)
Earnings DateN/A
Trade prices are not sourced from all markets
  • Morningstar2 days ago

    Third-Quarter Winners and Losers Among U.S. Stock Funds

    Domestic equities continued to reach new highs.

  • Blue Jay Capital Betting On Big Returns From These Healthcare Stocks
    Insider Monkey6 days ago

    Blue Jay Capital Betting On Big Returns From These Healthcare Stocks

    Founded by Paul Sinclair in August 2014, Blue Jay Capital Management is a healthcare-focused hedge fund based in California. Prior to founding Blue Jay Capital (named after Canada’s only current Major League Baseball team, the Toronto Blue Jays), Mr. Sinclair founded and ran another healthcare-focused hedge fund Expo Capital Management (named after the former Canadian MLB team the Montreal […]

  • Barrons.com7 days ago

    Mead Johnson: China Babies On The Way!

    No longer must Chinese parents stop their procreation at one child, and that should help U.S.-based Mead Johnson Nutrition (MJN) sell more infant formula. There is competition among formula sellers including France's Danone (DANOY), whose known brands are valued and can command premium prices in China after tampering and other health scares. But BMO Capital Markets Analyst Amit Sharma writes that "most investors do not expect the removal of one-child restrictions to have a meaningful impact on China's birth rates and on Mead Johnson's operating performance -- "at least in a reasonable investable time frame." BMO's Sharma disagrees. Sharma writes: " ... The expected 6%-11% annual increase in live births between 2017 and 2022 (vs. +0.5% in the last ten years) should lead to mid-single-digits incremental volume growth in the Chinese formula category (vs. low-single digits in the last five years).